contact@xenothera.com

[Newsletter] XENONEWS

June 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

More

[Press Alert] Safety and efficacy results of LIS1

June 2022. # Download our press information (english version) # Télécharger notre...

More

[Press Information] XENOTHERA presents LIS1 results at the American Transplant Congress (ATC) in Boston

May 2022. # Download our press information (english version) # Télécharger notre...

More

[ Press Information ] APPOINTMENTS

April 2022. # Download our press information (english version) # Télécharger notre...

More

[Newsletter] XENONEWS

February 2022. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

More

[Press information] XENOTHERA announces the continuation of development of its anti-SARS-CoV-2 antibody.

January 2022. # Download our press information (english version) # Télécharger notre...

More

[Press Alert] Omicron Variant : positive results for XENOTHERA's XAV-19 antibody

December 2021. # Download our press information (english version) # Télécharger notre...

More

[Newsletter] XENONEWS

December 2021. >> Official XENOTHERA’s newsletter /Lettre d’information officielle de XENOTHERA <<...

More

[ Press Information ]The French biotech XENOTHERA awarded Start-Up of the Year for the Western region.

# Download our press information (english version) # Télécharger notre information presse...

More